Condition

HIV I Infection

ClinicalTrials.gov condition label

Clinical trials31

Recruiting6

Common interventions25

Lead sponsors shown15

Clinical trials

31 shown

Multi Interventional Approaches to Mitigate HIV Reservoirs for the Sustained HIV Remission Without AntiretroviralsNCT06805656 · 2026-07-15

Real World Use of Lenacapavir, as an add-on to an Optimized Background Regimen in FranceNCT06799338 · 2025-03-03

Impact of Pain From Injectables Antiretroviral Treatments in HIV-1 Patients Based on the Injection Site (Ventrogluteal or Dorsogluteal) and the Use or Non-use of Virtual Reality HeadsetNCT06834113 · 2025-01-24

Evaluating the Safety and Immunogenicity of MTBVACNCT05947890 · 2024-01-30

Tnf Inhibitors to Reduce Mortality in HIV-1 Infected PAtients With Tuberculosis meNIngitisNCT05590455 · 2023-04-11

Low Dose Nivolumab in Adults Living With HIV on Antiretroviral TherapyNCT05187429 · 2023-01-24

The Expand Study-Pharmacist Administered Long Acting Cabotegravir + Rilpivirine to Expand Access for People With HIVNCT06635421 · 2024-11-01

NOT_YET_RECRUITING

Studying Topiramate for Re-Activating the HIV-1 ReservoirNCT06282783 · 2024-09-01

Cervical Pre-cancer Treatment Failure Among Women Living With HIV in ZimbabweNCT07202936 · 2024-05-03

ACTIVE_NOT_RECRUITING

Doravirine Versus Integrase Inhibitors on Backbone of Emtricitabine and Tenofovir Alafenamide in HIVNCT04820933 · 2024-03-01

ThiPhiSA: New Pathways to Prevention From Community TB Screening in South AfricaNCT06214910 · 2024-02-20

Estradiol Therapy In Transgender Women to Research Interactions With HIV TherapyNCT06005610 · 2024-01-04

To Investigate Safety, Reactogenicity and Immunogenicity of VIR-1388 Compared With Placebo in Participants Without HIVNCT05854381 · 2023-09-19

A Study Evaluating the Pharmacokinetics, Efficacy, Safety and Tolerability of CABENUVANCT05601128 · 2023-01-01

A Cohort Study of Use of Doravirine (DOR) Based Regimens in Clinical Practice in Europe DoRavirine Europe Real World/NCT05421806 · 2022-10-10

ACTIVE_NOT_RECRUITING

The Visceral Adiposity Measurement and Observation StudyNCT05383456 · 2022-04-18

Effect of a Mobile Health Intervention on Treatment AdherenceNCT05187741 · 2022-04-01

Early Empiric Anti-Mycobacterium Tuberculosis Therapy for Sepsis in Sub-Saharan AfricaNCT04618198 · 2022-01-05

Neuroinflammation and Neurodegeneration in HIV-positive Subjects Switched and Initially Treated With INSTINCT04887675 · 2021-05-01

Intervention to Improve HIV Care Retention by Addressing Stigma Stigmatized EnvironmentsNCT05110963 · 2021-02-01

ACTIVE_NOT_RECRUITING

Assessing the Impact of INSTI to PI Switch on Insulin Sensitivity and Fat MetabolismNCT04675255 · 2021-01-01

VIR-1111: A Prototype Human CMV-based Vaccine for Human Immunodeficiency Virus (HIV) in Healthy VolunteersNCT04725877 · 2020-12-28

Efficacy of Switching to DTG/3TC in Virologically-suppressed Adults Currently on B/F/TAFNCT04585737 · 2020-10-05

Acute Effects of TCIG vs ECIG in PLWHNCT04568395 · 2020-10-01

Leveraging Family-Based Assets for Black MSM In House Ball CommunitiesNCT05071378 · 2020-09-17

Access HIV Ag/Ab Combo Assay - European Union (EU) Clinical Trial ProtocolNCT04971343 · 2019-12-04

Role of the IL33/Amphiregulin Pathway as a Potential Therapeutic Target in HIV InfectionNCT03622177 · 2018-09-01

Charlotte Retention in Care StudyNCT03584048 · 2018-07-01

Community Based Antiretroviral Therapy (CBART) Among Children on Chronic ARTNCT03986099 · 2018-02-01

Safety and Efficacy of Romidepsin and the Therapeutic Vaccine Vacc-4x for Reduction of the Latent HIV-1 ReservoirNCT02092116 · 2014-03-01

Immunogenicity Study of Vacc-4x Versus Placebo in Patients Infected With HIVNCT00659789 · 2008-08-01

Common interventions

abdominal subcutaneous adipose tissue biopsyPROCEDURE1 Access HIV_blood donorDIAGNOSTIC_TEST1 Access HIV_Canada's requirements_Blood donorDIAGNOSTIC_TEST1 Access HIV_Canada's requirements_HIV positiveDIAGNOSTIC_TEST1 Access HIV_Canada's requirements_P24 PositiveDIAGNOSTIC_TEST1 Access HIV_Hospitalized patientDIAGNOSTIC_TEST1 Access HIV_known HIV-1 antibody positivesDIAGNOSTIC_TEST1 Access HIV_known HIV-1 p24 Ag positiveDIAGNOSTIC_TEST1 Access HIV_known HIV-2 antibody positivesDIAGNOSTIC_TEST1 Adalimumab InjectionDRUG1 Alert to providerOTHER1 AuranofinDRUG1 BCGBIOLOGICAL1 Behavioral Self-Regulation Skills CounselingBEHAVIORAL1 Behavioral Self-Regulation Skills Counseling + Stigma ManagementBEHAVIORAL1 Bictegravir / Emtricitabine / Tenofovir Alafenamide PillDRUG1 biopsiePROCEDURE1 blood drawnBIOLOGICAL1 CAB + RPVDRUG1 Clinic-link TPTOTHER1 Community-delivered TB preventive therapy (TPT) - 3 months weekly isoniazid plus rifapentine (3HP)OTHER1 Dendritic Cell VaccineBIOLOGICAL1 Diagnostic TestDIAGNOSTIC_TEST1 DolutegravirDRUG1 Dolutegravir / Lamivudine PillDRUG1

Leading sponsors

ANRS, Emerging Infectious Diseases2 Bionor Immuno AS2 National Institute of Allergy and Infectious Diseases (NIAID)2 Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)1 Beckman Coulter, Inc.1 Biomedical Research and Training Institute, Zimbabwe1 Centre de Recherches et d'Etude sur la Pathologie Tropicale et le Sida1 Centre Hospitalier Régional d'Orléans1 Charlotte-Paige Rolle, MD1 Epividian1 Erasmus Medical Center1 Federal University of São Paulo1 HIV Vaccine Trials Network1 Hospital Civil de Guadalajara1 MetroHealth Medical Center1

Trial status mix

COMPLETED16

RECRUITING6

UNKNOWN4

ACTIVE_NOT_RECRUITING3

NOT_YET_RECRUITING1

TERMINATED1

Phase mix

NA9

PHASE28

PHASE15

PHASE32

EARLY_PHASE11

PHASE41

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.